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Diaphragm weakness in mechanically ventilated
critically ill patients
Gerald S Supinski*† and Leigh Ann Callahan†
Abstract
Introduction: Studies indicate that mechanically ventilated patients develop significant diaphragm muscle
weakness, but the etiology of weakness and its clinical impact remain incompletely understood. We assessed
diaphragm strength in mechanically ventilated medical ICU patients, correlated the development of diaphragm
weakness with multiple clinical parameters, and examined the relationship between the level of diaphragm
weakness and patient outcomes.
Methods: Transdiaphragmatic twitch pressure (PdiTw) in response to bilateral magnetic stimulation of the phrenic
nerves was measured. Diaphragm weakness was correlated with the presence of infection, blood urea nitrogen,
albumin, and glucose levels. The relationship of diaphragm strength to patient outcomes, including mortality and
the duration of mechanical ventilation for successfully weaned patients, was also assessed.
Results: We found that infection is a major risk factor for diaphragm weakness in mechanically ventilated medical
ICU patients. Outcomes for patients with severe diaphragm weakness (PdiTw <10 cmH2O) were poor, with a
markedly increased mortality (49%) compared to patients with PdiTw ≥10 cmH2O (7% mortality, P = 0.022). In
addition, survivors with PdiTw <10 cmH2O required a significantly longer duration of mechanical ventilation (12.3 ±
1.7 days) than those with PdiTw ≥10 cmH2O (5.5 ± 2.0 days, P = 0.016).
Conclusions: Infection is a major cause of severe diaphragm weakness in mechanically ventilated patients.
Moreover, diaphragm weakness is an important determinant of poor outcomes in this patient population.
Introduction
The number of mechanically ventilated patients in med-
ical ICUs (MICUs) in the United States has increased
dramatically over the past 20 years. Currently 800,000
patients per year require mechanical ventilation [1].
Many of these patients die, with an annual mortality
exceeding 200,000 [2]. In addition, survivors often
require prolonged, expensive hospital stays to achieve
liberation from mechanical ventilation [3]. In the past it
was thought that the severity of lung disease was the
major determinant of outcomes in MICU patients, but
recent work indicates that mechanically ventilated
patients develop significant diaphragm weakness [4-6].
Diaphragm weakness is primarily thought to occur as a
consequence of ventilator-induced diaphragm inactivity,
with weakness progressing as duration of mechanical
ventilation increases [7,8]. Theoretically, however, there
are other mechanisms by which diaphragm weakness
can develop. Animal studies indicate that experimental
models of infection induce significant diaphragm weak-
ness [9,10]. In addition, data suggest that azotemia,
hyperglycemia, and low systemic albumin levels are risk
factors for prolonged mechanical ventilation and could
theoretically be associated with the development of
respiratory muscle weakness [11-13]. The importance of
infection, azotemia, hyperglycemia, and reduced albumin
levels as risk factors for the development of diaphragm
weakness in mechanically ventilated patients, however, is
unknown.
Diaphragm weakness is also commonly thought to pre-
dispose patients to sustained respiratory failure, greatly
prolonging the time required to wean patients from
mechanical ventilation and worsening clinical outcomes.
No previous study, however, has examined the quantita-
tive relationship of diaphragm function, assessed using a
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purely objective, nonvolitional technique (such as bilat-
eral anterior magnetic phrenic nerve stimulation), to clin-
ical outcomes in mechanically ventilated patients.
The purpose of the present study, therefore, was to
objectively measure diaphragm strength in a cross-
section of mechanically ventilated MICU patients and to
test the specific hypothesis that the severity of dia-
phragm weakness would correlate with one or more of
the following clinical factors: the presence of infection,
blood urea nitrogen level, serum albumin level, and/or
blood glucose level. We also ascertained the relationship
of diaphragm strength to patient outcomes, including
mortality, rate of transfer to long-term acute care
(LTAC) facilities, and the subsequent duration of
mechanical ventilation in MICU survivors who were
successfully extubated. Finally, to determine whether
clinicians were cognizant of the severity of diaphragm
weakness present in their patients, we asked the attend-
ing MICU physicians to estimate diaphragm strength
and compared these estimates with objectively deter-
mined measurements.
Methods
Study protocol
Studies were performed on adult ICU patients requiring
mechanical ventilation in the University of Kentucky
MICU for more than 24 hours. The protocol was
approved by the University of Kentucky Institutional
Review Board and informed consent was obtained from
subjects and their surrogates. The following were
recorded: diaphragm strength by measuring the trans-
diaphragmatic twitch pressure (PdiTw); respiratory static
system compliance and airway resistance using the
mechanical ventilator diagnostic module; basic clinical
data; clinician estimates of diaphragm strength; and out-
comes, including mortality, rate of transfer to LTAC
facilities, and additional days required for continued
mechanical ventilation until successful extubation.
Exclusion criteria
If the attending physician anticipated that the patient
would be successfully weaned from mechanical ventila-
tion in less than 24 hours, or determined that the
patient was too unstable to tolerate the measurements,
subjects were not screened for study inclusion. Exclu-
sion criteria included: requirement for high dose press-
ors (≥15 μg/minute norepinephrine or ≥15 mg/kg/
minute dopamine); elevated positive end-expiratory
pressure (PEEP ≥15 cmH2O); presence of a cardiac
pacemaker or implanted defibrillator; administration of
neuromuscular blocking agents within 48 hours prior to
study entry; recent variceal bleeding; pregnancy; incar-
ceration; or institutionalization.
Determination of transdiaphragmatic twitch pressure
Diaphragm strength was assessed by measuring PdiTw
in response to bilateral anterior magnetic stimulation of
the phrenic nerves. PdiTw is an objective, nonvolitional
technique that has been verified in previous studies to
provide the most accurate assessment of diaphragm
strength in humans [14-16]. Moreover, previous studies
demonstrate that this technique can reliably and repro-
ducibly measure diaphragm contractile strength in
mechanically ventilated ICU patients [4-6].
Subjects were studied in the supine position with the
head of the bed elevated at 30°. Two sterile commercially
available balloon-tipped catheters (Ackrad Laboratories,
NJ, USA) were passed through the nose after application
of local anesthetic (1 milliliter of 1% Lidocaine gel); one
catheter was placed in the stomach, while the other was
placed in the esophagus. Following initial placement, the
catheters were connected to Validyne pressure transdu-
cers (Validyne Engineering, Northridge, CA, USA) to
verify correct positioning. Correct placement of the gas-
tric balloon was confirmed by demonstrating a positive
pressure in response to pressure applied over the sto-
mach; correct placement of the esophageal balloon was
verified by demonstrating that the pressure waveform
had an end-expiratory pressure similar to the total PEEP
level and also mirrored airway pressure changes with
inspiratory efforts during airway occlusion.
After confirming accurate balloon placement, subjects
were left to breathe quietly for 10 minutes before
further assessment. Figure of eight magnetic coils
attached to dual Magstim 200 stimulators (Jali Medical,
Inc., Waltham, MA, USA) were then placed bilaterally
over the phrenic nerves adjacent to the border of the
sternocleidomastoid muscles. Magnetic field strength
was adjusted to maximal levels (100%) and simultaneous
supramaximal magnetic pulses were delivered to the
phrenic nerves bilaterally to elicit maximal twitch trans-
diaphragmatic pressures (that is, PdiTw). Stimuli were
interpolated between adjacent ventilator breaths and the
transdiaphragmatic pressures elicited by these stimuli
were recorded while simultaneously and transiently
occluding the external circuit connecting the endotra-
cheal tube to the ventilator with a pneumatic valve. A
minimum of five twitches were recorded, with at least
30 seconds between adjacent stimuli. To verify stimuli
were supramaximal, additional twitches were performed
at reduced magnetic field strengths (90 to 95%). PdiTw
was calculated as follows:
pdiTw =  gastric pressure −  esophageal pressure
The best three measurements in response to 100%
levels of magnetic stimulation were averaged for each
subject and recorded as the PdiTw.
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Measurement of respiratory system static compliance and
airway resistance
For these assessments, the ventilator was set to a
square-wave flow pattern with an inspiratory plateau.
The ventilator rate was then transiently increased (for
example, 30 to 60 seconds) to suppress spontaneous
respirations. After reaching a steady state, the peak pres-
sure and the plateau pressure were recorded and intrin-
sic PEEP was determined using an end-expiratory
occlusion maneuver. Inspiratory airway resistance of the
respiratory system was calculated as:
(Peak pressure - plateau pressure)
/
inspiratory flow
The effective static compliance of the respiratory sys-
tem was calculated as:
Tidal volume
/
(plateau pressure − (total PEEP))
Once measurements were completed, the ventilator
was returned to its previous mode and settings.
Clinical parameters
Data for the following clinical parameters were collected
as close as possible to the time of determination of
PdiTw levels: age, gender, clinical diagnoses, the pre-
sence of positive cultures for infectious agents, antibiotic
regimen, glucose, albumin, blood urea nitrogen (BUN),
Sequential Organ Failure Assessment scores, Charlson
comorbidity indexes, vital signs, duration of mechanical
ventilation prior to PdiTw measurement, mechanical
ventilation mode, FiO2 (fraction of inspired oxygen),
tidal volume and rate, percentage of patient triggered
breaths, and most recent arterial blood gas values. All
recorded values were obtained within 24 hours of
PdiTw assessment.
Clinician estimates
Attending physicians were asked to estimate the level of
diaphragm strength using a form with qualitative descrip-
tors of muscle weakness (see Additional file 1).
Statistical analysis
Whenever data were normally distributed and variances
were similar, parametric tests were used to compare
groups. When these conditions were not met, nonpara-
metric tests were used to make comparisons. Data analyzed
using parametric tests are presented as mean ± standard
error of the mean. Data analyzed using nonparametric tests
are presented as median ± confidence intervals. Linear
regression was utilized to assess the relationship of BUN,
albumin, glucose and duration of prior mechanical ventila-
tion to PdiTw level. Analysis of variance was employed to
compare PdiTw across cohorts of patients with different
levels of ventilator triggering. Fisher exact testing and
receiver operating curve analyses were used to determine
the boundary between weak and strong PdiTw groups that
best discriminated between survival and mortality [17].
Results
Diaphragm strength in medical ICU patients
Sixty subjects were recruited into the study. PdiTw could
not be measured in three subjects because the magnetic
coils could not be effectively positioned due to anatomic
constraints (Subjects 18, 43, and 48). Detailed informa-
tion for the 57 subjects in whom PdiTw measurements
were successfully performed is provided in Additional
file 2. To verify that we achieved supramaximal levels of
magnetic stimulation, we plotted the PdiTw values
achieved using 95% magnetic field strength levels against
PdiTw values attained using 100% magnetic field
strength, as shown in Figure 1A. The PdiTw levels
obtained using 95% and 100% field strength levels were
virtually identical, arguing that supramaximal neural sti-
mulation was achieved when employing 100% magnetic
field strength for these studies. Moreover, the twitch
determinations were highly reproducible in individual
subjects, with a coefficient of variation for the best three
measurements performed at 100% stimulator output
averaging 7% for the 57 subjects. High levels of PEEP can
alter the relationship between the actual intrinsic dia-
phragm strength and the measured PdiTw. In the present
cohort of patients, however, only one study subject had
PEEP >8 cmH2O. As a result, PEEP-induced hyperinfla-
tion did not appreciably impact our data analysis (see
Additional file 3).
This cohort of 57 mechanically ventilated subjects had a
mean PdiTw of 7.9 ± 0.6 cmH2O. This value is similar
to values reported previously in mechanically ventilated
critically ill patients [4-6]. For comparison, normal
healthy adults average a PdiTw of 29.3 ± 2.8 cmH2O in
our laboratory; this value is similar to that reported for
healthy adults in the literature [4,14]. Estimates of dia-
phragm strength from the attending physicians were
obtained for 51 subjects. Clinicians did not accurately
predict the level of diaphragm strength of their patients
(Figure 1B). In many cases, patients with profound levels
of diaphragm weakness were thought to have normal
strength. Strength was overestimated in 46 of 51
patients, was correctly estimated in five patients, and
was never underestimated.
Risk factors for the development of diaphragm weakness
Data were analyzed to determine which factors correlated
with the level of diaphragm weakness in mechanically ven-
tilated subjects. We found a strong relationship between
the presence of infection and diaphragm weakness. In all,
41 subjects were classified as being infected based on a
positive test for a pathogenic organism from a sterile site
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(40 patients) or a clinical diagnosis of bacterial pneumonia
(one patient; cultures were lost for this individual). All 41
subjects classified as infected were thought by the attend-
ing physicians who were providing care for these patients
to be infected clinically and all 41 of these patients
received antibiotic therapy (Tables 2 and 3). The
remaining 16 patients were classified as non-infected
(see Table 2). Infected patients had a median PdiTw of
only 5.5 cmH2O (25 to 75% confidence levels of 4.0 to
7.9 cmH2O), while patients without clinical evidence of
infection had a median PdiTw of 13.0 cmH2O (25
to 75% confidence levels of 11.0 to 14.7, P < 0.001)
(Figure 2A). Of interest, while infection was associated
with greater diaphragm weakness, infected patients did
not have significantly different respiratory mechanical
parameters (that is, respiratory system static compli-
ance and airway resistance) from non-infected patients
(Figure 2B, C).
We also found that there was no significant correlation
between PdiTw and either BUN, albumin, or glucose levels
(Figures 3A, B, C). While many patients were receiving
steroids (regimens provided in Table 3), we found no cor-
relation between steroid dosage and PdiTw values (see
Additional file 4). In addition, we found no relationship
between the number of days subjects had been on
mechanical ventilation prior to testing and the level of
PdiTw (Figure 4A). This finding contrasts with recent
reports suggesting that patients on mechanical ventilation
for longer durations have progressively lower levels of dia-
phragm strength [6,18]. One potential explanation for this
difference is that the patients examined in the present
study were all ventilated with assist modes of mechanical
ventilation, while previous work that demonstrated a
strong relationship between mechanical ventilation and
the development of diaphragm weakness specifically
restricted examination to patients who were on controlled
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Figure 1 Transdiaphragmatic twitch pressure: measured levels and physician estimates. (A) Transdiaphragmatic twitch pressure (PdiTw)
levels for the 57 subjects included in the analysis. Each symbol represents a single subject and plots the PdiTw level obtained in response to
stimulation of the phrenic nerves with 95% of maximum magnetic field strength (y axis) against the PdiTw obtained in response to stimulation
of the phrenic nerves with 100% of maximum magnetic field strength (x axis). All data cluster along the line of identity, indicating that
supramaximal stimulation was achieved during 100% magnetic field stimulation. If supramaximal conditions had not been achieved, data points
would have fallen to the right of the line of identity. (B) Measured PdiTw levels compared with levels predicted for each subject by their
attending physicians; each symbol represents data from a single patient. Red symbols below the line (46 out of 51 determinations) indicate
determinations for which physicians overestimated diaphragm strength (that is, PdiTw).
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mechanical ventilation with little or no spontaneous
respiratory activity [18]. As shown in Figure 4B, our
patient population had a high level of spontaneous respira-
tory activity, with the majority of patients triggering more
than 75% of ventilator breaths. Of interest, we also found
that PdiTw was similar over the range of levels of ventila-
tor triggering observed in the present study (Figure 4C).
Relationship of diaphragm strength to patient outcomes
To assess the relationship between diaphragm strength
and mortality, we plotted PdiTw against patient days of
survival (Figure 5A). Patients that died were significantly
weaker than survivors, with PdiTw averaging 6.3 ± 0.6
and 8.9 ± 0.9 cmH2O, respectively, for these two groups
(P < 0.04). To further analyze this relationship, we used
Fisher exact testing and ROC curve analyses to deter-
mine the level of PdiTw that best discriminated between
survival and mortality [17]. Both forms of testing found
this boundary to be 10 cmH2O. Patients with PdiTw
≥10 cmH2O had only a 7% mortality (one death out of
14 patients) while patients with PdiTw <10 cmH2O had
a 49% mortality (17 deaths out of 35 patients, P = 0.022
for comparison of the two groups; Figure 5B). Because
indices of lung function may influence mortality, we
also compared respiratory system static compliance and
airway resistance between patients with PdiTw ≥10
cmH2O and patients with Pdi <10 cmH2O (Figures 5C, D).
Lung mechanics were not significantly different between
these two groups of patients, indicating that level of dia-
phragm function, not lung function, best correlated with
survival in our patients. In addition, patients with PdiTw
≥10 cmH2O and PdiTw <10 cmH2O had similar Sequential
Organ Failure Assessment scores (7.6 ± 0.6 and 6.9 ± 0.4,
respectively) and Charlson Comorbidity Indices (2.7 ± 0.5
and 2.5 ± 0.3, respectively).
We also evaluated the possible mechanism(s) by which
diaphragm weakness may have influenced the incidence
of death. In this cohort, five of the patients with PdiTw
<10 cmH2O that died were receiving vasopressors when
care was withdrawn; vasopressors and mechanical venti-
lation were stopped simultaneously in these patients and
death occurred as a result of combined respiratory fail-
ure and hypotension. In the remaining 12 patients with
PdiTw <10 cmH2O that died, none met criteria for
brain death, all maintained motor drive to the respira-
tory pump, none were on vasopressors, and the only
form of continuous life support that these patients were
receiving was mechanical ventilation. Prior weaning
trials had been attempted and all 12 patients had failed
to reach extubation criteria. Death occurred in these 12
patients when mechanical ventilation was withdrawn.
These data suggest that the presence of severe dia-
phragm weakness limited weaning trial success in these
12 patients and may have influenced the decision to
withdraw care.
With respect to other outcome measures, seven patients
with PdiTw <10 cmH2O were transferred to a long-term
ventilator facility while only one of the patients with
PdiTw ≥10 cmH2O was transferred to a LTAC facility. In
addition, the time required to wean survivors from
mechanical ventilation was a function of PdiTw, with time
to wean increasing significantly for patients with PdiTw
<10 cmH2O (Figure 6A). On average, duration of mechan-
ical ventilation after PdiTw measurements was 12.3 ± 1.7
days for patients with PdiTw <10 cmH2O but only 5.5 ±
2.0 days for patients with PdiTw ≥10 cmH2O (P = 0.016).
In contrast, duration of mechanical ventilation had no
relationship to either respiratory system static compliance
(Figure 6B) or airway resistance (Figure 6C).
Discussion
The present study indicates that diaphragm weakness is a
significant determinant for poor outcomes in mechani-
cally ventilated MICU patients We found that the inci-
dence of death was 49% in the patients with the weakest
diaphragms (that is, with PdiTw <10 cmH2O) but was
only 7% for patients with PdiTw levels ≥10 cmH2O. One
possible explanation for the far greater mortality in
patients with PdiTw <10 cmH2O could be that weakness
is simply a marker for multiorgan system failure and that
damage to these other organs was primarily responsible
for patient deaths. Surprisingly, however, we found that
indices of disease severity (for example, lung mechanics,
Sequential Organ Failure Assessment scores, Charlson
Comorbidity Indexes) were almost identical in patients
with PdiTw levels ≥10 cmH2O and in patients with
PdiTw <10 cmH2O, suggesting that the relationship
between diaphragm weakness and mortality is not simply
an epiphenomenon. Moreover, the majority of patient
deaths (12 of 18 deaths) were the direct result of withdra-
wal of mechanical ventilatory support in weak patients
and, in each case, occurred after unsuccessful weaning
Table 1 Characteristics of non-infected and infected
study subjects
Non-infected
(n = 16)
Infected
(n = 41)
Age (years) 52.4 ± 14.1 55.5 ± 16.7
Gender (%)
Male 44 49
Female 56 51
Body mass index 30.3 ± 9.2 29.8 ± 9.5
Total ICU days 15.1 ± 9.8 34.9 ± 40.2
Days of MV before PdiTw
measurement
9.1 ± 8.9 10.4 ± 12.4
Steroid usage (%) 50 51
Data presented as mean ± standard deviation. MV, mechanical ventilation;
PdiTw, transdiaphragmatic twitch pressure.
Supinski and Ann Callahan Critical Care 2013, 17:R120
http://ccforum.com/content/17/3/R120
Page 5 of 17
Table 2 Classification of subjects according to presence/absence of active infection at time of PdiTw measurementsa
Subject
number
Infected Site Organism(s) isolated from site(s) Diagnosis of infection by
attending physician
Antibiotic
therapyb
Pulmonary
infiltrates
1 No No No No
2 Yes Liver abscess Staphylococcus sp., Fusobacterium
necrophorum
Yes Yes Yes
3 No No No No
4 Yes PAL Streptococcus pneumonia Yes Yes Yes
5 No No No No
6 Yes Blood Gram-positive bacteriac Yes Yes Yes
7 Yes PAL Pseudomonas aeruginosa Yes Yes Yes
8 Yes Blood Staphylococcus species Yes Yes Yes
9 No No No Yesd
10 Yes PAL Pseudomonas aeruginosa Yes Yes Yes
11 No No No No
12 Yes Sinuses Bacteroides capillosus, Fusobacterium
sp., b-strep. Gp C
Yes Yes Yes
Nasopharyngeal
swab
Influenza A
13 No No No No
14 Yes Jejunal drain VRE, Pseudomonas aeruginosa Yes Yes Yes
15 Yes Blood Staphylococcus aureus Yes Yes No
16 No No No No
17 Yes PAL Staphylococcus species Yes Yes Yes
Blood Staphylococcus species
19 Yes PAL Klebsiella pneumonia Yes Yes Yes
20 Yes Blood Staphylococcus aureus Yes Yes No
21 Yes Neck abscess Streptococcus sp. Yes Yes No
22 Yes Sputum Hemophilus parainfluenza Yes Yes Yes
23 Yes Stage IV
decubitus
Pseudomonas aeruginosa, Proteus
mirabilis
Yes Yes No
Urine Pseudomonas aeruginosa
24 No No No No
25 No No No No
26 No No No No
27 Yes Subphrenic
abscess
Candida glabrata Yes Yes Yes
28 No No No No
29 Yes BAL Escherichia coli, Klebsiella pneumoniae Yes Yes Yes
30 No No No No
31 No No No Yesd
32 Yes Blood Enterococcus faecalis Yes Yes No
33 Yes PAL Staphylococcus aureus Yes Yes Yes
34 Yes Blood Gram-positive coccic Yes Yes Yes
35 Yes ET aspirate Acinetobacter calcoaceticus,
Enterobacter cloacae
Yes Yes Yes
Blood Candida
36 Yes PAL Achromobacter xyloxosidans Yes Yes Yes
Central venous
catheter
Pseudomonas aeruginosa
37 Yes PAL Pseudomonas aeruginosa Yes Yes Yes
38 Yes Liver abscess Escherichia coli Yes Yes Yes
39 Yes PAL Staphylococcus sp., Enterobacter
aerogenes, Escherichia coli
Yes Yes Yes
40 Yes PAL MRSA Yes Yes Yes
Blood MRSA
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Table 2 Classification of subjects according to presence/absence of active infection at time of PdiTw measurementsa
(Continued)
41 Yes Nasopharyngeal
swab
Influenza B Yes Yes Yes
42 Yes Blood MRSA Yes Yes Yes
Leg abscess MRSA
Osteomyelitis MRSA
44 No No No Yesd
45 No No No No
46 Yes Sputum MRSA Yes Yes Yes
47 Yes PAL Streptococcus pneumonia Yes Yes Yes
49 No No No No
50 Yes Pleural fluid Acinetobacter baumannii, VRE Yes Yes Yes
Pleural tissue Acinetobacter baumannii, VRE
51 Yes Blood Bacillus circulans Yes Yes Yes
52 Yes Blood VRE Yes Yes Yes
53 Yes PAL Pseudomonas aeruginosa Yes Yes Yes
Nasopharyngeal
swab
H1N1
54 Yes Blood VRE Yes Yes Yes
Tracheal aspirate Stenotrophomonas maltophilia
55 Yes PAL MRSA Yes Yes Yes
56 Yes Blood MRSA, Pseudomonas aeruginosa, VRE Yes Yes Yes
Sputum Pseudomonas aeruginosa
57 Yes BAL Samples loste Yes Yes Yes
58 Yes Tracheal aspirate Hemophilus influenza Yes Yes Yes
59 Yes Blood Staphylococcus species Yes Yes No
60 Yes Urine Enterobacter cloacae Yes Yes Yes
PAL Streptococcus sp.
aData not included for Subjects 18, 43, and 48 because transdiaphragmatic twitch pressure (PdiTw) measurements were not obtained due to anatomic
constraints. bPatient on antibiotic therapy at the time of PdiTw measurement. cOrganism not speciated - subject treated with antibiotics prior to transfer.dPatient
with pulmonary infiltrates but without evidence of infection (Subject 9 with nonpulmonary acute lung injury, Subject 31 with pulmonary fibrosis, Subject 44 with
acute respiratory distress syndrome). eBronchoscopy performed with purulent exudates noted; specimens lost in transit to laboratory. BAL, bronchoalveolar
lavage; MRSA, methicillin-resistant Staphylococcus aureus; PAL, protected alveolar lavage; VRE, Enterococcus faecium (vancomycin-resistant).
Table 3 Medication regimen in 57 subjects at the time of transdiaphragmatic twitch pressure measurementsa
Subject
number
Antibiotics Other medications Steroid regimen over entire ICU stay
1 Midazolam, metoprolol, hydralazine, calcium acetate,
famotidine
2 Piperacillin/tazobactam,
vancomycin, levofloxacin,
flagyl
Enoxaparin, omeprazole, dobutamine Hydrocortisone 100 mg every 8 hours × 4 days
3 Metoprolol, haloperidol, insulin, aspirin
4 Piperacillin/tazobactam,
vancomycin, levofloxacin
Midazolam, fentanyl, pantoprazole
5 Famotidine, trazadone Methylprednisolone 1 g/day × 3 days, prednisone
60 mg/day × 2 days, 40 mg/day × 3 days, 30 mg/day ×
2 days, 20 mg/day × 2 days, 10 mg/day × 2 days
6 Piperacillin/tazobactam,
vancomycin, fluconazole
Midazolam, fentanyl, insulin, lactulose, levothyroxine,
norepinephrine, pantoprazole
Hydrocortisone 50 mg every 6 hours × 1 day
7 Piperacillin/tazobactam Midazolam, alprazolam, fentanyl, insulin, famotidine,
heparin
8 Vancomycin Midazolam, fentanyl, insulin, famotidine, heparin,
simvastatin, gabapentin, venlafaxine, calcium
gluconate
Hydrocortisone 50 mg every 8 hours × 8 days
Supinski and Ann Callahan Critical Care 2013, 17:R120
http://ccforum.com/content/17/3/R120
Page 7 of 17
Table 3 Medication regimen in 57 subjects at the time of transdiaphragmatic twitch pressure measurementsa
(Continued)
9 Midazolam, lorazepam, omeprazole, ursodiol,
clonidine, levetiracetam, ondansetron,
metaclopramide, hydralazine, heparin
10 Piperacillin/tazobactam,
vancomycin
Midazolam, famotidine, aspirin, clopidogrel, insulin,
heparin, metaclopramide, docusate
Prednisone 20 mg/day × 3 days, Hydrocortisone
100 mg every 8 hours × 2 days
11 Midazolam, protonix, amitryptyline, bupropion,
carvedilol, clonazepam, folic acid, acetaminophen,
digoxin, ondansetron, heparin, tacrolimus
Methylprednisolone 60 mg every 12 hours × 3 days
12 Vancomycin, clindamycin,
tamiflu
Midazolam, fentanyl, morphine, heparin, insulin,
pantoprazole, bumetanide
Methylprednisolone 60 mg/day × 4 days, prednisone
40 mg/day × 3 days
13 Midazolam, enoxaparin, famotidine, insulin,
metoprolol, aspirin, hydralazine, lisinopril, simvastatin
14 Vancomycin, levofloxacin,
flagyl, aztreonam
Midazolam, fentanyl, heparin Methylprednisolone 60 mg every 12 hours × 6 days
15 Vancomycin Propofol, omeprazole, heparin, amlodipine
16 Midazolam, fentanyl, protonix, ondansetron,
darbepoetin, folic acid, cyanocobalamin, hydralazine,
amldipine, lisinopril
17 Vancomycin, levofloxacin Midazolam, fentanyl, protonix, insulin, lactulose,
levothyroxine, sertraline, hydralazine, gabapentin,
carvedilol
19 Vancomycin, piperacillin/
tazobactam, levofloxacin
Heparin, hydralazine, labetalol, metoprolol,
levetiracetam, lorazepam, omeprazole, phenytoin
Prednisone 20 mg/day × 2 days
20 Vancomycin Midazolam, morphine, amlodipine, labetalol,
metoprolol, protonix, phenytoin, heparin
21 Vancomycin, tobramycin,
ampicillin/sulbactam
Midazolam, fentanyl, heparin, ibuprofen, amiodarone,
metoprolol, omeprazole
22 Vancomycin, levofloxacin Famotidine, heparin, metaclopramide,
diphenhydramine
23 Vancomycin, doripenem,
colistin
Bumetanide, midazolam, ascorbic acid, famotidine,
insulin, vitamin A, zinc, aripiprazole, escitalopram,
heparin
24 Paroxetine, pramipexole, simvastatin, omeprazole,
heparin, midazolam, insulin, metoprolol, bumetanide
25 Midazolam, heparin, omeprazole, haloperidol,
olanzapine, insulin
Prednisone 40 mg/day × 6 days
26 Famotidine, darbepoetin, amlodipine, labetolol, folic
acid, thiamine, dexmedetomidine, heparin
27 Doripenem, doxycycline,
micafungin, flagyl
Midazolam, fentanyl, promethazine, pantoprazole,
levetiracetam, propofol, lactulose
Prednisone 50 mg every 8 hours × 8 days
28 Midazolam, haloperidol, omeprazole, levothyroxine,
heparin, insulin, furosemide
29 Doripenem, tobramycin,
fluconazole, erythromycin
Morphine, ondansetron, rifaximin, pantoprazole,
lactulose, insulin, aspirin, heparin, levetriacetam,
midazolam, phenytoin, vasopressin
30 Aspirin, benztropine, famotidine, gabapentin,
hydrochlorothiazide, metoclopramide, miralax, insulin,
heparin, valproic acid, docusate
Methylprednisolone 125 mg every 6 hours × 2 days
31 Azathioprine, bumetanide, clopidogrel, ezetimibe,
famotidine, fentanyl, furosemide, heparin, metoprolol,
midazolam, nitroglycerin patch, omeprazole,
provastatin
Methylprednisilone 125 mg every 6 hours × 3 days,
40 mg every 6 hours × 2 days, prednisone
60 mg/day × 5 days
32 Vancomycin, gentamycin,
aztreonam
Midazolam, fentanyl, aspirin, carbemazepam,
haloperidol, metoprolol, omeprazole, phenytoin,
insulin, heparin
Methylprednisolone 60 mg every 6 hours × 6 days
33 Linezolid Midazolam, lorazepam, fentanyl, aspirin, digoxin,
insulin, metoprolol, famotidine, heparin
34 Vancomycin, piperacillin/
tazobactam, micofungin
Midazolam, fentanyl, insulin, aspirin, amlodipine,
metaclopramide, famotidine, heparin
Methylprednisolone 100 mg every 12 hours × 9 days
35 Vancomycin, piperacillin/
tazobactam, micofungin,
colistin, bactrim
Foscarnate, pantoprazole, diphenhydramine, insulin,
fludrocortisone, levothyroxine, ursodiol
Methylprednisolone 10 mg × 1 day
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Table 3 Medication regimen in 57 subjects at the time of transdiaphragmatic twitch pressure measurementsa
(Continued)
36 Vancomycin,
meraopenum,
valgancyclovir, cefipime,
dapsone, levofloxacin
Ondansetron, omeprazole, metoprolol,
mycophenolate mofetil, sildenafil
Prednisone 25 mg/day × 250 days
37 Piperacillin/tazobactam,
vancomycin, levofloxacin
Midazolam, fentanyl, aspirin, heparin, omeprazole,
simvastatin
Methylprednisolone 40 mg/day × 2 days, prednisone
40 mg/day × 1 day, prednisone 20 mg/day × 3 days
38 Flagyl, levofloxacin,
aztreonam
Midazolam, fentanyl, morphine, norepinephrine,
vasopressin, famotidine, heparin
39 Doripenam, colistimethate,
vancomycin
Midazolam, fentanyl, lortab, zolpidem, metoprolol,
omeprazole, heparin
40 Vancomycin, piperacillin/
tazobactam, levofloxacin
Midazolam, fentanyl, metaclopramide, aspirin,
azathioprine, clopidogrel, furosemide, ondansetron,
simvastatin, famotidine, heparin
Prednisone 20 mg/day × 7 days
41 Vancomycin, piperacillin/
tazobactam, clindamycin
Midazolam, fentanyl, propofol, insulin, omeprazole
42 Vancomycin, cefipime,
levofloxacin, acyclovir
Midazolam, fentanyl, ondansetron, pantoprazole,
heparin
44 Midazolam, fentanyl, haloperidol, insulin, famotidine,
heparin
Methylprednisolone 125 mg every 6 hours × 2 days
45 Midazolam, fentanyl, ondansetron, insulin,
omeprazole, heparin
Hydrocortisone 100 mg every 8 hours × 3 days
46 Linezolid, piperacillin/
tazobactam, tobramycin
Midazolam, Diltiazem, mycophenolate mofetil,
tacrolimus, famotidine, insulin, heparin
Hydrocortisone 100 mg every 8 hours × 6 days,
prednisone 40 mg/day × 3 days
47 Vancomycin, cefipime,
levofloxacin
Midazolam, aspirin, captopril, furosemide, simvastatin,
insulin
Prednisone 40 mg/day × 3 days, 30 mg/day × 2 days
49 Midazolam, aspirin, atorvastatin, bisoprolol,
clopidogrel, fluticasone, folic acid, pantoprazole,
heparin
Methylprednisolone 60 mg every 6 hours × 4 days,
40 mg every 12 hours × 2 days, prednisone
40 mg/day × 1 day
50 Vancomycin, aztreonam,
tobramycin, daptomycin
Midazolam, hydroxyzine, darbepoetin, levothyroxine,
ferrous sulfate, ergocalciferol, pancrelipase,
omeprazole
Hydrocortisone 20 mg every 12 hours × 37 days
51 Vancomycin, piperacillin/
tazobactam, doripenam,
fluconazaole
Midazolam, fentanyl, furosemide, pancrelipase,
magnesium oxide, famotidine, insulin, heparin
52 Vancomycin, piperacillin/
tazobactam, daptomycin
Midazolam, fentanyl, levothyroxine, darbepoetin,
fluticasone, lactulose, paroxetime, insulin, heparin
Hydrocortisone 100 mg every 8 hours × 5 days
53 Tamiflu, piperacillin/
tazobactam, cefipime,
daptomycin, doripenam
Midazolam, darbepoetin, bumetanide, famotidine,
insulin, heparin
54 Vancomycin, piperacillin/
tazobactam
Morphine, oxycodone, furosemide, famotidine, insulin,
heparin
Hydrocortisone 50 mg every 6 hours × 3 days
55 Vancomycin, piperacillin/
tazobactam, levofloxacin,
daptomycin
Ferrous sulfate, folic acid, levothyroxine,
metaclopramide, pravastatin, digoxin tacrolimus,
omeprazole, heparin
56 Daptomycin, linezolid,
tobramycin, colistin,
zithromax
Midazolam, fentanyl, dexmedetomidine, omeprazole,
heparin
57 Vancomycin, piperacillin/
tazobactam, levofloxacin,
tamiflu
Midazolam, fentanyl, clonazepam, gabapentin,
famotidine, insulin, heparin
58 Piperacillin/tazobactam Midazolam, morphine, furosemide, metoprolol,
citalopram, pantoprazole, aspirin, acetazolamide,
insulin, heparin
Methylprednisolone 60 mg every 8 hours × 4 days,
prednisone 60 mg/day × 5 days, 40 mg/day ×
5 days, 30 mg/day × 5 days
59 Vancomycin, cefipime,
levofloxacin
Midazolam, fentanyl, dopamine, norepinephrine,
simvastatin, aspirin, omeprazole, heparin
Hydrocortisone 100 mg every 8 hours × 3 days, 50
mg every 8 hours × 2 day, 50 mg every 12 hours ×
7 days
60 Vancomycin, cefipime,
tobramycin
Midazolam, fentanyl, norepinephrine, pantoprazole,
heparin
aData not included for Subjects 18, 43, and 48 because transdiaphragmatic twitch pressure measurements not obtained due to anatomic constraint.
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Figure 2 Infection and diaphragm weakness. (A) Transdiaphragmatic twitch pressure (PdiTw) measurements for non-infected and infected
patients. Data from individual patients are shown for each group on the right, while plots on the left for each group show mean (filled squares),
median levels (middle line of box), 25% and 75% confidence intervals (upper and lower borders of the box) and 1% and 99% intervals (whiskers
above and below the box). Infection was associated with significant lower Pdi Twitch values (*statistical significance). (B) respiratory system (RS)
static compliance and (C) inspiratory airway resistance for non-infected and infected patients; there was no difference in these indices of lung
function between non-infected and infected groups.
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Figure 3 Correlation of transdiaphragmatic twitch pressure to blood urea nitrogen, albumin, and glucose levels. Transdiaphragmatic
twitch pressure (PdiTw) as a function of (A) blood urea nitrogen (BUN), (B) albumin, and (C) glucose levels. There was no significant correlation
between any these parameters and PdiTw. Specifically, correlation coefficients and P values for regression of PdiTw to parameters were,
respectively, 0.146 and 0.277 for BUN, 0.072 and 0.596 for albumin, and 0.032 and 0.815 for glucose levels (all nonsignificant).
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Figure 4 Relationship of prior duration of mechanical ventilation and ventilator triggering to diaphragm strength .
(A) Transdiaphragmatic twitch pressure (PdiTw) as a function of the duration of mechanical ventilation prior to measurement of PdiTw. There
was no statistically significant correlation of PdiTw to duration of ventilation prior to measurement, with a correlation coefficient of 0.020 and
P = 0.881 for this assessment (nonsignificant). (B) The majority of subjects actively initiated (that is, triggered) ventilator breaths more than 75%
of the time. (C) The level of diaphragm strength (PdiTw) did not correlate with the level of triggering, with the same PdiTw observed at all
triggering levels.
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Figure 5 Relationship of diaphragm strength to survival. (A) Survival of patients (days after measurement, x axis) as a function of
transdiaphragmatic twitch pressure (PdiTw) level (y axis). Patients that died had low average PdiTw levels (6.3 ± 0.6 cmH2O) while survivors had
higher PdiTw levels (8.9 ± 0.9 cmH2O, P = 0.044). (B) Survival curves for subjects with PdiTw ≥10 cmH2O (n = 15) and PdiTw <10 cmH2O (n =
42). Weak subjects had a significantly higher mortality (49%) than strong subjects (7%, P = 0.022). To exclude the possibility that the greater
mortality in the weakest patients may have been due to the presence of more severe lung dysfunction, we also examined (C) respiratory system
(RS) static compliance and (D) airway resistance. There was no significant difference in RS static compliance or airway resistance for patients with
PdiTw ≥10 cmH2O and PdiTw <10 cmH2O, indicating that the greater mortality ion the weakest patients was not due to concomitant lung
dysfunction.
Supinski and Ann Callahan Critical Care 2013, 17:R120
http://ccforum.com/content/17/3/R120
Page 13 of 17
attempts. Weakness almost certainly contributed to the
inability to wean these patients from mechanical ventila-
tion and thereby may have influenced the decision to
withdraw care.
We also found that a high percentage of patients with
PdiTw <10 cmH2O required transfer to LTAC units.
Reports indicate that long-term outcomes for this group
of patients are poor, with a high percentage (51%) dying
Figure 6 Relationship of diaphragm strength to ventilator weaning duration. (A) Duration of mechanical ventilation after measurement of
transdiaphragmatic twitch pressure (PdiTw) as a function of the level of PdiTw; each symbol represents data from a single subject. Patients with
PdiTw ≥10 cmH2O required significantly shorter times to wean from mechanical ventilation when compared with patients with PdiTw <10
cmH2O (P = 0.016). The time required to wean from mechanical ventilation bore no relationship, however, to (B) the respiratory system (RS)
static compliance or (C) the airway resistance.
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within 1 year [19]. As a result, the high rate of transfer of
weak patients to these units represents a poor outcome.
In addition, we found that the relationship between dia-
phragm strength and duration of mechanical ventilation
for patients that did not die and remained in the ICU was
curvilinear, with duration increasing progressively as
PdiTw levels fell to lower values (Figure 6A). Weak
patients with PdiTw <10 cmH2O required more than
twice as long to wean from mechanical ventilation than
stronger patients with PdiTw levels ≥10 cmH2O. More-
over, the duration of mechanical ventilation did not cor-
relate with the level of lung dysfunction but only with the
level of diaphragm strength.
We also evaluated our data to ascertain the role of
infections, BUN, albumin and glucose levels in the induc-
tion of diaphragm weakness in mechanically ventilated
patients. We found the level of diaphragm weakness in
mechanically ventilated MICU patients did not correlate
with BUN, glucose, or albumin levels despite previous
reports associating these factors with prolonged mechani-
cal ventilation [11-13]. In contrast, we found that
evidence of infection was a predictor of strikingly lower
levels of diaphragm strength than that observed for non-
infected patients. This finding is consistent with multiple
previous animal studies demonstrating that infection
rapidly reduces diaphragm force generation, decreases
diaphragm mitochondrial function, activates diaphragm
proteolytic pathways, and reduces diaphragm contractile
protein function [9,20-26].
While infected patients had the weakest diaphragms,
even the non-infected mechanically ventilated patients in
our study had a median level of PdiTw (13 cmH2O),
which is substantially lower than that observed for nor-
mal healthy adults (30 cmH2O). There are at least two
potential explanations for the weakness observed in the
non-infected patients. First, many of the patients in our
study were chronically ill, with multiple comorbid condi-
tions including heart failure, malignancy, liver and renal
diseases. Each of these entities has negative effects on
muscle function, and it is possible that the pre-intubation
muscle function of these patients may have been appreci-
ably lower than that observed in normal subjects.
In addition, use of mechanical ventilation can result in
diaphragm inactivity and atrophy [27-30]. Numerous
animal studies have provided evidence of this phenom-
enon, and, more recently, several elegant studies indicate
that loss of diaphragm function occurs in patients who
are subjected to controlled mechanical ventilation with
minimal or no spontaneous respirations [18,27]. Our
patients were all ventilated using assisted modes of
mechanical ventilation and may therefore have had less
inactivity-induced diaphragm dysfunction than observed
in patient populations ventilated with controlled modes
of mechanical ventilation. Nevertheless, it is still possible
that ventilator-induced inactivity contributed to the level
of diaphragm weakness observed in our non-infected
patients. As a corollary, the level of weakness observed
in our infected patients may represent the combined
effects of chronic illness, ventilator-induced inactivity,
and infection-induced diaphragm dysfunction.
One should note, however, that the non-infected
patients had a level of PdiTw (median of 13 cmH2O) that
was sufficiently high for this group of patients to be
expected to have good outcomes (that is, a low death rate
and an average wean time from mechanical ventilation of
about 5 days) according to the data presented in Figures 5
and 6. Only the infected mechanically ventilated patients,
as a group, had low enough PdiTw levels (median of 5.5
cmH2O) to expect poor outcomes (that is, a high mortality
and a protracted need for mechanical ventilation). These
data therefore argue that even if all of the diaphragm
weakness observed in our non-infected patients was a con-
sequence of ventilator-induced inactivity, this level of
weakness alone would not be expected to result in poor
patient outcomes. Our data would instead suggest that
only the combination of ventilator-induced inactivity and
infection may produce sufficient diaphragm weakness to
negatively influence patient survival and duration of
mechanical ventilation.
Conclusions
In summary, we found that mechanically ventilated MICU
patients have severe diaphragm weakness, that the clini-
cians caring for these patients greatly underestimate the
severity of diaphragm weakness present, and that infec-
tions are a major risk factor for the development of dia-
phragm weakness in this population. We also found that
diaphragm weakness was associated with poor patient out-
comes, including a significantly increased mortality, an
increased transfer to LTACs and a markedly longer dura-
tion required for weaning from mechanical ventilation.
Diaphragm weakness appears to be a major risk factor
for respiratory failure and death in mechanically venti-
lated MICU patients; theoretically, pharmacological
treatments that improve diaphragm strength should
reduce the duration of mechanical ventilation and
MICU mortality. Currently no such agents are used in
clinical practice, but recent experimental studies indicate
that pharmacological inhibition of selected cellular path-
ways can prevent diaphragm weakness in animal models
of critical illness [31,32]. There is an urgent need to
translate these pharmacological treatments from the
bench to the bedside in order to prevent or reverse dia-
phragm weakness in mechanically ventilated MICU
patients. Such therapies are likely to influence both
acute and long-term outcomes.
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Key messages
• Recent work indicates that many mechanically ven-
tilated MICU patients have severe diaphragm weak-
ness, but the causes and consequences of this
weakness remain controversial.
• The present study indicates that infection is a
major risk factor for development of diaphragm
weakness in MICU patients treated with assist
modes of mechanical ventilation.
• This work also demonstrates that the level of dia-
phragm weakness is a novel predictor of clinical out-
comes; the weakest patients have a high mortality and
require prolonged durations of mechanical ventilation.
• This study indicates that clinicians underestimate
the severity of diaphragm dysfunction in mechani-
cally ventilated critically ill patients.
Additional material
Additional file 1: presents additional methods.
Additional file 2: Table S1 presenting the demographic and clinical
data in 57 subjects who underwent PdiTw measurements.
Additional file 3: Figure S1. Relationship of PdiTw values to PEEP
levels. PdiTw values are shown as a function of PEEP levels. We found
no correlation between the level of PEEP and PdiTw measurements. The
correlation coefficient and p value for regression of PdiTw to PEEP were
0.093 and 0.492, respectively (NS).
Additional file 4: Figure S2. Effect of Steroids on PdiTw values.
Cumulative dosages of steroids was calculated and converted into
hydrocortisone equivalents, then plotted as a function of PdiTw. As shown,
steroid dosage had no relationship to measured PdiTw. The correlation
coefficient and p value for regression of PdiTw to hydrocortisone
equivalents were 0.064 and 0.637, respectively (NS).
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